Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.49 |
| ▸ | OGA | O60502 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132220 | 1.00 | HRH3 (0.64) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL6132267 | 1.00 | HRH3 (0.64) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL9204223 | 0.90 | HRH3 (0.73) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL9210226 | 0.89 | HRH3 (0.72) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL6132498 | 0.87 | HRH3 (0.61) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL6132503 | 0.87 | HRH3 (0.61) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL6132837 | 0.87 | HRH3 (0.61) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL6132162 | 0.87 | HRH3 (0.52) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL6132274 | 0.85 | RAB9A (0.53) | HRH3NPC1RAB9AADRA1AALDH1A1 | |
| SCHEMBL6132270 | 0.85 | RAB9A (0.53) | HRH3NPC1RAB9AADRA1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6884774-B2 | Cyclic hexapeptide derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1259535-B1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20030083238-A1 | Cyclic hexapeptide derivatives | ASTELLAS PHARMA INC. (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1259535-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060846-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083238-A1 | Cyclic hexapeptide derivatives | NGLY1, ALG1, CHIT1 | HRH3 2597/4885NPC1 2414/4885RAB9A 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.